Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
Justin F Gainor, Daniel SW Tan, Tomasso De Pas, Benjamin J Solomon, Aziah Ahmad, Chiara Lazzari, Filippo de Marinis, Gianluca Spitaleri, Katherine Schultz, Luc Friboulet, Beow Y Yeap, Jeffrey A Engelman, Alice T Shaw
CLINICAL CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2015
PURPOSE: Anaplastic lymphoma kinase (ALK) rearrangements are important therapeutic targets in non-small cell lung cancer (NSCLC) that confer sensitivity to the ALK inhibitors crizotinib and ceritinib. To determine the outcome of sequential treatment with crizotinb and ceritinib, we retrospectively evaluated a cohort of ALK-positive patients treated with both agents. EXPERIMENTAL DESIGN: We identified 73 ALK-positive NSCLC patients treated with crizotinib followed by ceritinib at four institutions. Medical records were reviewed to determine overall survival (OS) and progression-free survival (PFS) on crizotinib and ceritinib. RESULTS: Among 73 ALK-positive patients, the median PFS (mPFS) on c..View full abstract
Awarded by U.S. National Institutes of Health
Awarded by NATIONAL CANCER INSTITUTE
This work was supported by grants from the U.S. National Institutes of Health 5R01CA164273, 5P50CA090578-10, and C06CA059267.